ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
October 21, 2014

AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress

Read More
October 02, 2014

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

Read More
October 02, 2014

Lupuzor™ Gears Up To Start Pivotal Phase III trials

Read More
June 27, 2014

ANNUAL GENERAL MEETING: 2014

Read More
June 27, 2014

ImmuPharma to access pioneering research in the Bordeaux region of France

Read More
June 16, 2014

New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency

Read More
June 09, 2014

PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013

Read More
May 23, 2014

Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014

Read More
May 06, 2014

Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference

Read More
April 23, 2014

Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan

Read More
April 11, 2014

ImmuPharma Sponsors the 2014 European Lupus Conference

Read More
August 13, 2013

UPDATE: Cancer Programme IPP-204106

Read More
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved